Dr. Beer on the Implications of the PREVAIL Study

Tomasz Beer, MD, FACP
Published Online: Monday, February 3, 2014
Tomasz Beer, MD, FACP, professor of Medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, discusses the treatment of metastatic castration-resistant prostate cancer (mCRPC) with abiraterone and enzalutamide as it relates to results from the PREVAIL study.

Beer says that is a wonderful time to contemplate how two effective drugs could both be used for patients in this space. As the PREVAIL study was not designed to compare abiraterone and enzalutamide, it cannot be said that one drug is superior or inferior.

A decision to treat with abiraterone or enzalutamide must be made on a physician-by-physician and patient-by-patient basis as there are specific considerations to be made. For example, Beer notes, enzalutamide does not require steroids, so for patients for whom giving steroids is a concern, enzalutamide may be preferred.

Beer says that there are many differences in the two studies and the data that may help a physician make decisions.

<<< View more from the 2014 GU Cancers Symposium

Online CME Activities
Free CME from PER
Cancer Summaries and Commentaries: Update from Chicago – Advanced Gastrointestinal Cancers
Cancer Summaries and Commentaries: Update from Chicago – Skin Cancer and Other Cutaneous Malignancies
Oncology Briefing: Advances in Estrogen Receptor-Positive Breast Cancer
Coping With Confidence: Online Clinical Case Discussions
More Reading
Publications
$auto_registration$